keyword
MENU ▼
Read by QxMD icon Read
search

SCLC

keyword
https://www.readbyqxmd.com/read/28737478/family-matters-how-myc-family-oncogenes-impact-small-cell-lung-cancer
#1
Johannes Brägelmann, Stefanie Böhm, Matthew R Guthrie, Gurkan Mollaoglu, Trudy G Oliver, Martin L Sos
Small cell lung cancer (SCLC) is one of the most deadly cancers and currently lacks effective targeted treatment options. Recent advances in the molecular characterization of SCLC has provided novel insight into the biology of this disease and raises hope for a paradigm shift in the treatment of SCLC. We and others have identified activation of MYC as a driver of susceptibility to Aurora kinase inhibition in SCLC cells and tumors that translates into a therapeutic option for the targeted treatment of MYC-driven SCLC...
July 24, 2017: Cell Cycle
https://www.readbyqxmd.com/read/28723866/a-case-of-resistance-to-tyrosine-kinase-inhibitor-therapy-small-cell-carcinoma-transformation-concomitant-with-plasma-genotyped-t790m-positivity
#2
Yanjun Xu, Zhiyu Huang, Lei Gong, Yun Fan
Although non-small-cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations are responsive to EGFR-tyrosine kinase inhibitors, drug resistances are always inevitable. The secondary somatic EGFR threonine-methionine substitution at position 790 (T790M) mutation accounts for ∼50% of acquired resistance mechanisms. Small cell lung cancer (SCLC) transformation is a relatively rare mechanism, but has recently attracted considerable attention. The coexistence of both the mechanisms in one patient is much more scarce in clinic...
July 18, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28722674/evaluation-of-factors-associated-with-platinum-sensitivity-status-and-survival-in-limited-stage-small-cell-lung-cancer-patients-treated-with-chemoradiotherapy
#3
Qiang Wen, Xue Meng, Peng Xie, Shijiang Wang, Xindong Sun, Jinming Yu
In this retrospective study, we analyzed the association of clinicopathological factors and therapeutic plans with platinum-sensitivity status and survival of limited-stage small cell lung cancer (LS-SCLC) patients. We enrolled 452 LS-SCLC patients with 279 platinum sensitive and 173 platinum refractory patients. The low serum neuro-specific enolase levels (NSE; p = 0.011), neutrophil-to-lymphocyte ratios (NLR; p = 0.013) and higher objective response rates (p = 0.003) were associated with sensitive group but not the refractory group...
July 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28720459/investigating-the-role-of-human-papillomavirus-in-lung-cancer
#4
E Argyri, E Tsimplaki, C Marketos, G Politis, E Panotopoulou
Lung cancer is the leading cancer worldwide among men and women with morbidity reaching 1.6 million. Human Papillomavirus is the causal factor of cervical cancer while its association with others is still under investigation. The purpose of our study is to examine the presence of HPV DNA as well as high-risk E6/E7 mRNA in patients with lung cancer. Lung tissues were collected during bronchoscopy and tested for HPV DNA and E6/E7 mRNA. 67 lung tissue samples were analysed. The age range was 49-85 years old (y...
June 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/28719656/phenotypic-characterization-of-circulating-tumor-cells-in-the-peripheral-blood-of-patients-with-small-cell-lung-cancer
#5
Ippokratis Messaritakis, Eleni Politaki, Athanasios Kotsakis, Eleftheria-Kleio Dermitzaki, Filippos Koinis, Eleni Lagoudaki, Anastasios Koutsopoulos, Galatea Kallergi, John Souglakos, Vassilis Georgoulias
BACKGROUND: To evaluate the phenotypic heterogeneity of circulating tumor cells (CTCs) based on the expression of proliferative, apoptotic and Epithelial-to-Mesenchymal Transmission (EMT) markers during front-line treatment in patients with small cell lung cancer (SCLC) and to evaluate their clinical relevance. METHODS: CTCs from 108 chemotherapy-naïve patients with SCLC were analyzed by double immunofluorescence staining using anti-Ki67, anti-M30, anti-Vimentin along with anti-CKs antibodies...
2017: PloS One
https://www.readbyqxmd.com/read/28714472/targeting-the-differential-addiction-to-anti-apoptotic-bcl-2-family-for-cancer-therapy
#6
Akane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, Hui-Chen Chen, Song Han, Yogesh Tengarai Ganesan, Kota Ishizawa, Sylvia Jebiwott, Yiyu Dong, Maria C Pietanza, Matthew D Hellmann, Mark G Kris, James J Hsieh, Emily H Cheng
BCL-2 family proteins are central regulators of mitochondrial apoptosis and validated anti-cancer targets. Using small cell lung cancer (SCLC) as a model, we demonstrated the presence of differential addiction of cancer cells to anti-apoptotic BCL-2, BCL-XL or MCL-1, which correlated with the respective protein expression ratio. ABT-263 (navitoclax), a BCL-2/BCL-XL inhibitor, prevented BCL-XL from sequestering activator BH3-only molecules (BH3s) and BAX but not BAK. Consequently, ABT-263 failed to kill BCL-XL-addicted cells with low activator BH3s and BCL-XL overabundance conferred resistance to ABT-263...
July 17, 2017: Nature Communications
https://www.readbyqxmd.com/read/28709456/analyses-of-distribution-and-dosimetry-of-brain-metastases-in-small-cell-lung-cancer-with-relation-to-the-neural-stem-cell-regions-feasibility-of-sparing-the-hippocampus-in-prophylactic-cranial-irradiation
#7
Lei Zhao, Yan Shen, Jin-Dong Guo, Heng-Le Gu, Wen Yu, Jia-Ming Wang, Chang-Xing Lv, Jun Liu, Xu-Wei Cai, Xiao-Long Fu
BACKGROUND: This work aims to assess the feasibility of selectively sparing the hippocampus during prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC). METHODS: SCLC patients with brain metastases (BMs) diagnosed with MRI were enrolled. Lesions localized to the neural stem cell (NSC) compartments [subventricular zone (SVZ) or hippocampus] were analyzed. Patients were categorized by the total number of intracranial metastases, the therapy processes and the symptoms...
July 15, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28707433/comparison-of-irinotecan-platinum-versus-etoposide-platinum-chemotherapy-for-extensive-stage-small-cell-lung-cancer-a-meta-analysis
#8
D Han, G Wang, L Sun, X Ren, W Shang, L Xu, S Li
This meta-analysis was performed to compare the effects and toxicities between irinotecan/platinum (IP) and etoposide/platinum (EP) regimens as the fist-line treatment of patients with extensive-stage small cell lung cancer (E-SCLC). A systematic search was made of MEDLINE, Cochrane, ISI Web of Science and SCOPUS databases. Randomised clinical trials on treatment of E-SCLC with the IP regimens, compared with EP regimens, were reviewed. Studies were pooled to hazard ratio (HR), relative risk (RR) and odds ratio (OR), with 95% confidence interval (CI)...
July 13, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28706293/small-cell-lung-cancer-model-of-circulating-tumor-cell-tumorospheres-in-chemoresistance
#9
Lukas Klameth, Barbara Rath, Maximilian Hochmaier, Doris Moser, Marlene Redl, Felicitas Mungenast, Katharina Gelles, Ernst Ulsperger, Robert Zeillinger, Gerhard Hamilton
Small cell lung cancer (SCLC) represents 15% of lung cancers and is characterized by early dissemination, development of chemoresistance and a poor prognosis. A host of diverse drugs failed invariably and its mechanisms of global chemoresistance have not been characterized so far. SCLC represents the prototype of an aggressive and highly metastatic tumor which is ultimately refractory to any treatment. High numbers of circulating tumor cells (CTCs) allowed us to establish 5 CTC cell lines (BHGc7, 10, 16, 26 and UHGc5) from patients with recurrent SCLC...
July 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28698410/combination-treatment-of-rad001-and-bez235-exhibits-synergistic-antitumor-activity-via-down-regulation-of-p-4e-bp1-mcl-1-in-small-cell-lung-cancer
#10
Bo Hong, Huogang Wang, Ke Deng, Wei Wang, Haiming Dai, Vivian Wai Yan Lui, Wenchu Lin
Small cell lung cancer (SCLC) is a highly malignant cancer with few targeted therapies. In the study, by mining the Cancer Cell Line Encyclopedia (CCLE) database, we found that PI3K/AKT/mTOR pathway was aberrant in 92% of SCLC cell lines. Moreover, we found that the phosphorylation level of 4E-BP1 was significantly correlated with SCLC sensitivity to RAD001 (mTOR inhibitor) and BEZ235 (PI3K/mTOR dual inhibitor). Combination of RAD001 and BEZ235 synergistically inhibited the growth of SCLC cells, which was accompanied by enhanced induction of cell cycle arrest and apoptosis...
July 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28698200/targeting-axl-and-mtor-pathway-overcomes-primary-and-acquired-resistance-to-wee1-inhibition-in-small-cell-lung-cancer
#11
Triparna Sen, Pan Tong, Lixia Diao, Lerong Li, Youhong Fan, Jennifer Hoff, John Heymach, Jing Wang, Lauren A Byers
Purpose: Drugs targeting DNA repair and cell cycle checkpoints have emerged as promising therapies for small cell lung cancer (SCLC). Among these, the WEE1 inhibitor AZD1775 has shown clinical activity in a subset of SCLC patients, but resistance is common. Understanding primary and acquired resistance mechanisms will be critical for developing effective WEE1 inhibitor combinations. <p>Experimental Design: AZD1775 sensitivity in SCLC cell lines was correlated with baseline expression level of 200 total or phosphorylated proteins measured by reverse phase protein array (RPPA) to identify predictive markers of primary resistance...
July 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28693444/the-value-of-ultrasound-guided-biopsy-of-fluorodeoxy-glucose-positron-emission-tomography-fdg-pet-positive-supraclavicular-lymph-nodes-in-patients-with-suspected-lung-cancer
#12
Lennart Werner, Franziska Aebersold Keller, Ujwal Bhure, Justus Egidius Roos, Katharina Tornquist, Maria Del Sol Pèrez-Lago, Oliver Gautschi, Klaus Strobel
BACKGROUND: Accurate lymph node staging is essential for adequate prognostication and therapy planning in patients with non-small cell lung cancer (NSCLC). FDG-PET/CT is a sensitive tool for the detection of metastases, including non-palpable supraclavicular lymph node (SCLN) metastases. Histological proof of metastatic spread and mutation analysis is crucial for optimal staging and therapy. The aim of this study was to investigate the value of ultrasound-guided fine needle aspiration cytology (FNAC) and core biopsy (CB) of FDG active, non-palpable SCLN's in patients with suspicion for lung cancer...
July 11, 2017: BMC Medical Imaging
https://www.readbyqxmd.com/read/28693276/examination-of-the-predictive-factors-of-the-response-to-whole-brain-radiotherapy-for-brain-metastases-from-lung-cancer-using-mri
#13
Shuri Aoki, Tomonori Kanda, Noriyuki Matsutani, Nobuhiko Seki, Masafumi Kawamura, Shigeru Furui, Hideomi Yamashita
Previous studies have been conducted on the prognostic factors for overall survival in patients with brain metastases (BMs) following whole brain radiotherapy (WBRT). However, there have been a small number of studies regarding the prognostic factors for the response of tumor to WBRT. The aim of the present study was to identify the predictive factors for the response to WBRT from the point of view of reduction of tumor using magnetic resonance imaging. A retrospective analysis of 62 patients with BMs from primary lung cancer treated with WBRT was undertaken...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28693218/meta-analysis-of-the-role-of-bevacizumab-in-extensive-stage-small-cell-lung-cancer
#14
Yan-Juan Zhu, Hai-Bo Zhang, Yi-Hong Liu, Jian-Ping Bai, Yong Li, Li-Rong Liu, Yan-Chun Qu, Xin Qu, Xian Chen
Progress in the treatment options for small cell lung cancer (SCLC) remains poor. Concerns exist regarding the efficacy of bevacizumab in SCLC. The present study aimed to evaluate the efficacy of bevacizumab in extensive stage (ES)-SCLC. A meta-analysis on studies conducted and listed on the Medline, Cochrane Trials, ASCO, ESMO and ClinicalTrial databases, and Chinese databases prior to April 2015 was performed. All clinical trials in which patients with ES-SCLC were treated with bevacizumab were considered...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28693210/resistance-to-epithelial-growth-factor-receptor-tyrosine-kinase-inhibitors-in-a-patient-with-transformation-from-lung-adenocarcinoma-to-small-cell-lung-cancer-a-case-report
#15
Liying Fang, Jian He, Jingwen Xia, Liang Dong, Xiujuan Zhang, Yaqin Chai, Ying Li, Mengjie Niu, Tianxing Hang, Shengqing Li
First-generation epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly improved the treatment of non-small cell lung cancer (non-SCLC) with EGFR-sensitive mutations. However, acquired resistance to these drugs was inevitable. The transformation of lung adenocarcinoma to SCLC following treatment with EGFR-TKIs is a rare phenomenon that contributes to resistance to EGFR-TKIs. The present case concerns a 74-year-old man previously diagnosed with and treated for pneumonia; however, this was later pathologically confirmed as lung adenocarcinoma by transbronchial lung biopsy...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28690012/prognostic-value-of-metabolic-parameters-of-metastatic-lymph-nodes-on-18-f-fdg-pet-ct-in-patients-with-limited-stage-small-cell-lung-cancer-with-lymph-node-involvement
#16
Feng Jin, Bo Qu, Zheng Fu, Yan Zhang, Anqin Han, Li Kong, Jinming Yu
INTRODUCTION: We assessed the prognostic value of the metabolic parameters of different lesions, including primary tumors and metastatic lymph nodes (LNs), measured by fluorine-18 fluorodeoxyglucose positron emission tomography (PET)/computed tomography in patients with limited-stage small-cell lung cancer (LS-SCLC) with LN metastasis. MATERIALS AND METHODS: The present retrospective study included 46 patients with clinical stage II-III N1-N2 LS-SCLC who had undergone pretreatment fluorine-18 fluorodeoxyglucose PET/computed tomography scanning from January 2011 to December 2014...
June 22, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28685088/modified-glasgow-prognostic-score-in-patients-with-small-cell-lung-cancer
#17
Koichi Kurishima, Hiroko Watanabe, Hiroichi Ishikawa, Hiroaki Satoh, Nobuyuki Hizawa
Systemic inflammatory response, which represents the presence of cachexia, is observed often in patients with lung cancer. To evaluate the prognostic significance of the presence of a systemic inflammatory response in small cell lung cancer (SCLC) patients, a retrospective study using modified Glasgow prognostic Score (mGPS) was performed. This score is composed of serum albumin and C-reactive protein levels. All the patients with SCLC who were diagnosed in Tsukuba University Hospital, Tsukuba Medical Center Hospital and Mito Medical Center between April 1999 and July 2016 were included in this study...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28679770/therapy-of-small-cell-lung-cancer-sclc-with-a-topoisomerase-i-inhibiting-antibody-drug-conjugate-adc-targeting-trop-2-sacituzumab-govitecan
#18
Jhanelle E Gray, Rebecca S Heist, Alexander N Starodub, D Ross Camidge, Ebenezer A Kio, Gregory A Masters, W Thomas Purcell, Michael J Guarino, Jamal Misleh, Charles J Schneider, Bryan J Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A Messersmith, Serengulam V Govindan, Pius P Maliakal, Boyd Mudenda, William A Wegener, Robert M Sharkey, David M Goldenberg
Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small-cell lung cancer (mSCLC) patients. <p>Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1-7) mSCLC who received either 8 or 10 mg/kg i.v. on days 1 and 8 of 21-day cycles. The primary endpoints were safety and objective response rate (ORR); duration of response, progression-free survival (PFS), and overall survival (OS) were secondary endpoints.</p> <p>Results: Sixty percent of patients showed tumor shrinkage from baseline CTs...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28678434/prospective-study-of-proton-beam-radiation-therapy-for-limited-stage-small-cell-lung-cancer
#19
Jean-Claude M Rwigema, Vivek Verma, Liyong Lin, Abigail T Berman, William P Levin, Tracey L Evans, Charu Aggarwal, Ramesh Rengan, Corey Langer, Roger B Cohen, Charles B Simone
BACKGROUND: Existing data supporting the use of proton-beam therapy (PBT) for limited-stage small cell lung cancer (LS-SCLC) are limited to a single 6-patient case series. This is the first prospective study to evaluate clinical outcomes and toxicities of PBT for LS-SCLC. METHODS: This study prospectively analyzed patients with primary, nonrecurrent LS-SCLC definitively treated with PBT and concurrent chemotherapy from 2011 to 2016. Clinical backup intensity-modulated radiotherapy (IMRT) plans were generated for each patient and were compared with PBT plans...
July 5, 2017: Cancer
https://www.readbyqxmd.com/read/28675754/inverted-structural-quantum-dot-light-emitting-diodes-based-on-al-doped-zno-electrode
#20
Zhaobing Tang, Jie Lin, Lishuang Wang, Jinsong Luo, Jialong Zhao, Hai-Bo Li, Yunjun Wang, Xingyuan Liu
As an indium-free transparent conducting film, Al-doped zinc oxide (AZO) was prepared by magnetron sputtering technique, exhibiting good electrical, optical and surface characteristics. UPS/XPS measurements show that AZO and zinc oxide nanoparticles (ZnO NPs) have matched energy level that can facilitate the electron injection from AZO to ZnO NPs. Inverted structural green quantum dot light-emitting diodes based on AZO cathode were fabricated, which exhibits a maximum luminance up to 178000 cd/m<sup>2</sup>, and a maximum current efficiency of 10...
July 4, 2017: Nanotechnology
keyword
keyword
37726
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"